369 related articles for article (PubMed ID: 15665300)
21. A mouse embryonic stem cell model of Schwann cell differentiation for studies of the role of neurofibromatosis type 1 in Schwann cell development and tumor formation.
Roth TM; Ramamurthy P; Ebisu F; Lisak RP; Bealmear BM; Barald KF
Glia; 2007 Aug; 55(11):1123-33. PubMed ID: 17597122
[TBL] [Abstract][Full Text] [Related]
22. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications.
Gottfried ON; Viskochil DH; Couldwell WT
Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723
[TBL] [Abstract][Full Text] [Related]
23. Stimulus-evoked release of neuropeptides is enhanced in sensory neurons from mice with a heterozygous mutation of the Nf1 gene.
Hingtgen CM; Roy SL; Clapp DW
Neuroscience; 2006; 137(2):637-45. PubMed ID: 16298082
[TBL] [Abstract][Full Text] [Related]
24. NF1 modulates the effects of Ras oncogenes: evidence of other NF1 function besides its GAP activity.
Corral T; Jiménez M; Hernández-Muñoz I; Pérez de Castro I; Pellicer A
J Cell Physiol; 2003 Nov; 197(2):214-24. PubMed ID: 14502561
[TBL] [Abstract][Full Text] [Related]
25. Molecular targets for emerging anti-tumor therapies for neurofibromatosis type 1.
Dilworth JT; Kraniak JM; Wojtkowiak JW; Gibbs RA; Borch RF; Tainsky MA; Reiners JJ; Mattingly RR
Biochem Pharmacol; 2006 Nov; 72(11):1485-92. PubMed ID: 16797490
[TBL] [Abstract][Full Text] [Related]
26. Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells.
Mangoura D; Sun Y; Li C; Singh D; Gutmann DH; Flores A; Ahmed M; Vallianatos G
Oncogene; 2006 Feb; 25(5):735-45. PubMed ID: 16314845
[TBL] [Abstract][Full Text] [Related]
27. Neurofibromin: a general outlook.
Trovó-Marqui AB; Tajara EH
Clin Genet; 2006 Jul; 70(1):1-13. PubMed ID: 16813595
[TBL] [Abstract][Full Text] [Related]
28. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity.
Tong J; Hannan F; Zhu Y; Bernards A; Zhong Y
Nat Neurosci; 2002 Feb; 5(2):95-6. PubMed ID: 11788835
[TBL] [Abstract][Full Text] [Related]
29. NF1 tumor suppressor protein and mRNA in skeletal tissues of developing and adult normal mouse and NF1-deficient embryos.
Kuorilehto T; Nissinen M; Koivunen J; Benson MD; Peltonen J
J Bone Miner Res; 2004 Jun; 19(6):983-9. PubMed ID: 15125795
[TBL] [Abstract][Full Text] [Related]
30. A mouse model for the learning and memory deficits associated with neurofibromatosis type I.
Silva AJ; Frankland PW; Marowitz Z; Friedman E; Laszlo GS; Cioffi D; Jacks T; Bourtchuladze R
Nat Genet; 1997 Mar; 15(3):281-4. PubMed ID: 9054942
[TBL] [Abstract][Full Text] [Related]
31. The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.
Solga AC; Toonen JA; Pan Y; Cimino PJ; Ma Y; Castillon GA; Gianino SM; Ellisman MH; Lee DY; Gutmann DH
Oncotarget; 2017 Jul; 8(29):47206-47215. PubMed ID: 28525381
[TBL] [Abstract][Full Text] [Related]
32. Heterozygosity for the neurofibromatosis 1 (NF1) tumor suppressor results in abnormalities in cell attachment, spreading and motility in astrocytes.
Gutmann DH; Wu YL; Hedrick NM; Zhu Y; Guha A; Parada LF
Hum Mol Genet; 2001 Dec; 10(26):3009-16. PubMed ID: 11751683
[TBL] [Abstract][Full Text] [Related]
33. Neurofibromatosis 1: closing the GAP between mice and men.
Dasgupta B; Gutmann DH
Curr Opin Genet Dev; 2003 Feb; 13(1):20-7. PubMed ID: 12573431
[TBL] [Abstract][Full Text] [Related]
34. Neurofibroma-associated growth factors activate a distinct signaling network to alter the function of neurofibromin-deficient endothelial cells.
Munchhof AM; Li F; White HA; Mead LE; Krier TR; Fenoglio A; Li X; Yuan J; Yang FC; Ingram DA
Hum Mol Genet; 2006 Jun; 15(11):1858-69. PubMed ID: 16648142
[TBL] [Abstract][Full Text] [Related]
35. Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (NF1) gene.
Thomas L; Richards M; Mort M; Dunlop E; Cooper DN; Upadhyaya M
Hum Mutat; 2012 Dec; 33(12):1687-96. PubMed ID: 22807134
[TBL] [Abstract][Full Text] [Related]
36. Tumorigenic properties of neurofibromin-deficient Schwann cells in culture and as syngrafts in Nf1 knockout mice.
Wu M; Wallace MR; Muir D
J Neurosci Res; 2005 Nov; 82(3):357-67. PubMed ID: 16180234
[TBL] [Abstract][Full Text] [Related]
37. Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11.
Flotho C; Steinemann D; Mullighan CG; Neale G; Mayer K; Kratz CP; Schlegelberger B; Downing JR; Niemeyer CM
Oncogene; 2007 Aug; 26(39):5816-21. PubMed ID: 17353900
[TBL] [Abstract][Full Text] [Related]
38. Molecular genetic analyses in neurofibromatosis type 1 patients with tumors.
Oguzkan S; Terzi YK; Cinbis M; Anlar B; Aysun S; Ayter S
Cancer Genet Cytogenet; 2006 Mar; 165(2):167-71. PubMed ID: 16527612
[TBL] [Abstract][Full Text] [Related]
39. Activation of the tyrosinase gene promoter by neurofibromin.
Suzuki H; Takahashi K; Yasumoto K; Shibahara S
Biochem Biophys Res Commun; 1994 Dec; 205(3):1984-91. PubMed ID: 7811291
[TBL] [Abstract][Full Text] [Related]
40. Neurofibromatosis 1 (NF1) heterozygosity results in a cell-autonomous growth advantage for astrocytes.
Bajenaru ML; Donahoe J; Corral T; Reilly KM; Brophy S; Pellicer A; Gutmann DH
Glia; 2001 Mar; 33(4):314-23. PubMed ID: 11246230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
